Up next

Autoplay

Clinical Trial Results of New Agent for Myelodysplastic Syndromes and Acute Myeloid Leukemia

0 Views • 07/04/23
Share
Embed
administrator
administrator
Subscribers
0

Raoul Tibes, M.D., Ph.D., hematologist and scientist at Mayo Clinic in Arizona, discusses Phase I clinical trial results of a new agent, SGI-110, a DNA hypomethylating agent, for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2012.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay